Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

ClinicalTrials.gov ID: NCT00766090

Public ClinicalTrials.gov record NCT00766090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare once and twice daily GW685698 in asthma

Study identification

NCT ID
NCT00766090
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
190 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2008 (Type not available)
Primary completion
Mar 2009 (Actual)
Completion
Mar 2009 (Actual)
Last update posted
Dec 8, 2016

2008 – 2009

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
GSK Investigational Site Long Beach California 90806 —
GSK Investigational Site Long Beach California 90808 —
GSK Investigational Site Torrance California 90505 —
GSK Investigational Site Cocoa Florida 32927 —
GSK Investigational Site Tallahassee Florida 32308 —
GSK Investigational Site Bethesda Maryland 20814 —
GSK Investigational Site Columbia Missouri 65203 —
GSK Investigational Site Rolla Missouri 65401 —
GSK Investigational Site Raleigh North Carolina 27607 —
GSK Investigational Site Canton Ohio 44718 —
GSK Investigational Site Medford Oregon 97504 —
GSK Investigational Site Orangeburg South Carolina 29118 —
GSK Investigational Site Austin Texas 78750 —
GSK Investigational Site Boerne Texas 78006 —
GSK Investigational Site San Antonio Texas 78229 —
GSK Investigational Site Waco Texas 76712 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00766090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2016 · Synced Oct 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00766090 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →